Introduction
Tissue reperfusion following a period of ischemia triggers a complement-dependent inflammatory reaction that culminates in necrotic and apoptotic cell death. A seminal study by Weiser et al., 1 established that following ischemia and reperfusion (IR) of skeletal muscle, complement is activated by self-reactive natural IgM antibodies (Abs) that bind to post-ischemic tissue. So-called natural IgM Abs are produced mainly by the B-1 subset of B lymphocytes, and the screening of hybridomas generated from an enriched B-1 cell fraction led to the identification of an IgM mAb that recognized non-muscle myosin expressed in reperfused tissues 2, 3 . Our recent studies have identified additional targets for self-reactive natural Abs on post-ischemic tissue, namely annexin IV and a subset of phospholipids that are expressed in the post-ischemic intestine and brain 4, 5 . Thus, the above studies suggest that ischemia-induced neoepitopes or corresponding self-reactive natural Abs represent targets for therapeutic intervention of ischemia reperfusion injury (IRI). To date, however, studies have not addressed the role of these Abs/epitopes in the unique setting of transplantation, which involves periods of both cold and warm ischemia, and global organ IRI.
The complement system is also a potential target for therapeutic intervention of IRI 6 .
However, complement inhibitors have met with limited success in the clinic, and there are currently only 2 FDA approved complement inhibitors: an anti-C5 mAb and recombinant C1-inhibitor. These biologics have thus far had minimal health impact since they have only been approved for orphan diseases and are extremely expensive. The two approved inhibitors, as well as most other complement inhibitors that have been investigated, systemically inhibit complement, although it is known that targeting a complement inhibitor to deposited complement fragments can improve bioavailability and significantly improve the efficacy of issue, namely annexin IV and a subset of phospholipids that are expressed in the he e pos o o t t--is is i ch ch chem em emi ic ntestine and brain 4, 5 . Thus, the above studies suggest that ischemia-induced neoepitopes or co orr rr res es esp po pond nd ndin in ing g se e elf lf lf-r -reactive natural Abs represen n nt t t ta a argets for therap ap apeu uti ti ic c c in intervention of ischemia complement inhibition 7 . Here, we demonstrate that natural self-reactive IgM mAbs induce posttransplant complement activation and IRI. Based on IgM target identification, we developed a novel bi-functional reagent that both blocks the binding of pathogenic IgM and targets a complement inhibitor specifically to post-ischemic cardiac endothelium. The reagent is a fusion protein consisting of an annexin IV-specific single chain antibody (scFv) linked to Crry. Annexin IV is a target for natural self-reactive Abs, and Crry is a murine inhibitor of C3 activation that is a structural and functional analogue of human CR1, a soluble untargeted form of which is in clinical trials. With regard to clinical translation, there are significant potential advantages of the therapeutic strategy described here compared to other complement inhibitory approaches, including a previously described CR2-targeted approach 7 (see discussion), and there is also strong evidence that the post-ischemic annexin IV recognition system described here similarly functions in humans 4, 5, 8 .
Methods
See also the Methods section in the online-only Data Supplement
Cell lines and antibodies
The B4 and C2 hybridoma cell lines expressing IgM mAbs were isolated following the fusion of spleen cells from unmanipulated wt C57BL/6 mice as described 5 . The specificities of these mAbs have been determined; B4 mAb recognizes annexin IV 5 and C2 mAb recognizes a subset of phospholipids 4 . As a control Ab, we used IgM mAb F632, expressed by a hybridoma isolated from mice immunized with 4-hydroxy-3-nitrophenylacetyl (NP)-KLH and screened against NP-BSA, as described 5 .
Transplantation Studies
Male C57BL/6, Rag1-/-on C57BL/6 background, and BALB/c mice were used in these studies.
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Downloaded from
For isograft studies, we used the following experimental groups: 1. C57BL/6 donors and recipients; 2. Rag1-/-donors and recipients; 3. Rag1-/-donors and recipients with administration of 0.1 mg B4 mAb to recipient; 4. Rag1-/-donors and recipients, with administration of 0.1 mg C2 mAb to recipient; 5. Rag1-/-donors and recipients with administration of 0.1 mg B4 mAb and 0.1 mg C2 mAb to recipient; 6. Rag1-/-donors and recipients with administration of 0. 
Construction and expression of recombinant proteins
For construction of B4 and C2 ScFv expressing plasmids, mRNA was prepared from corresponding hybridomas described above (details in Data Supplement). For construction of the B4 scFv-Crry expression plasmid, the B4scFv sequence was linked to the extracellular region of mouse Crry (residues 1-319 of mature protein, GenBank accession number NM013499) by overlapping PCR with the linker (G 4 S 2 ) 2 , and OKT3 light chain signal peptide sequence added to the 5' end of the VH chain. Recombinant proteins were expressed in CHO cells and purified by anti-His tag affinity chromatography (for B4 and C2 scFv's) or anti-Crry affinity chromatography (for B4 scFv-Crry) as described 7 .
Statistics
GraphPad Prism version 5.0 for Mac OS X (GraphPad, San Diego, CA) and SAS version 9.2 (SAS Institute Inc, Cary, NC) were used for statistical analysis. Differences between various were performed according to approved experimental protocols in accordance wi ith th h i ins n n ti ti titu tu tuti ti tion on onal al animal care guidelines of the Medical University of South Carolina.
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pairwise comparisons were made to analyze the key questions of the effect of B4scFv and B4scFv-Crry on IRI outcome; specifically comparisons between control and B4scFv, control and B4scFv-Crry, control and B4scFv-Crry plus C2 mAb, and B4scFv and B4scFv-Crry. For analysis of survival, SAS Proc LIFETEST was used to conduct log-rank tests for comparing survival across the 3 groups. All analyses were two-sided and a p<0.05 was deemed significant.
Results

IgM mAbs restore cardiac IRI in Rag1-/-recipient mice
To investigate the role of self-reactive natural IgM in post-transplant cardiac IRI, we assessed IRI in isografts after transplantation from C57BL/6 wt donors to either Ab deficient Rag1-/-recipients or Rag1-/-recipients reconstituted with a specific IgM mAb. Following transplantation, Rag1-/-recipients were reconstituted with either B4 or C2 mAbs, or a combination of both mAbs. These mAbs have been shown previously to recognize post-ischemic neoepitopes in the intestine and brain 4, 5 . B4 recognizes annexin IV 5 and C2 recognizes a subset of phospholipids 4 . Anti-NP mAb F632 (see methods) was used as a control Ab. Compared to grafts in wild type (wt) recipients, grafts in Rag1-/-recipients were protected from posttransplant cardiac IRI as evidenced by reduced histologic injury and inflammation, and decreased serum levels of cardiac troponin I (an index of cardiac cell damage). However, reconstitution of Rag1-/-recipients with either B4 or C2 mAbs, but not F632 mAb, restored graft IRI to that seen in wt recipients. Furthermore, compared to administration of B4 and C2 mAbs individually, there was no increase in injury when B4 and C2 mAbs were co-administered (Figure 1 ).
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Analysis of IgM binding and complement activation
The graft specificity and binding characteristics of B4 and C2 mAbs in Rag1-/-recipients was investigated by immunohistochemical analysis of graft sections. Both B4 and C2 mAbs bound to endothelial cells of arterioles, capillaries, and microvessels within the myocardium of the transplanted heart (Figure 2A) , but not the native heart (not shown). Additional Ab binding in grafts was seen on myocytes, with localization to injured myocytes in the epicardium. The staining pattern in grafts was similar whether recipients were treated individually with B4 or C2 mAbs or with combined B4 + C2 mAbs. No IgM immunostaining was detected in grafts from Rag1-/-recipients treated with F623 control mAb (Figure 2A ) or in native hearts (not shown).
The above data together demonstrate that annexin IV and a previously identified subset of phospholipids are post-ischemically expressed in the transplanted heart, and that IgM recognition of these epitopes is associated with graft IRI. Additionally, IgM deposition in grafts from recipients treated with B4, C2 or a combination of B4 + C2 mAbs, was associated with intragraft complement activation as determined by the presence of C3d in the microvasculature in a similar staining pattern to that for IgM (Figure 2A ). C3d was absent or barely detectable in grafts from recipients treated with PBS or control F632 mAb.
Based on the above data, we investigated whether a post-ischemic cardiac neoepitope may represent a specific therapeutic target for complement inhibition. Since there was no detectable difference between B4 and C2 mAbs in terms of their graft binding characteristics and their ability to restore graft IRI in Rag1-/-recipients, we chose B4 mAb as the focus for further studies since it is known that annexin IV is expressed on human hypoxic endothelial cells 4 , and
IgM reactivity to annexin IV is present in human serum 5 . To additionally confirm that the B4 epitope represents an appropriate target for complement inhibition, we demonstrated that B4
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Natural IgM Abs are known to activate the lectin pathway following myocardial ischemia and reperfusion in a non-transplant setting 9 . However, by immunohistochemistry we were unable to detect MBL-A, MBL-C (or C1q) in grafts 6 hours post-transplantation. Whereas C3d is a long-lived opsonin at sites of complement activation, it is possible that the 6 hour time point (chosen because this is when we see maximal injury and inflammation post-transplant) misses the window of MBL binding/detection. In any case, while we cannot confirm that the lectin pathway is activated by IgM in this transplant setting, the targeted complement inhibitor we develop in this study inhibits all complement pathways at the downstream C3 activation step.
Preparation and initial characterization of neoepitope-targeted B4scFv
Our planned strategy for neoepitope-targeted complement inhibition involves linking a complement inhibitor to a B4-derived scFv. Such a construct has the potential to not only target complement inhibition to the post-ischemic graft, but also to inhibit the binding of specific selfreactive pathogenic IgM to the reperfused graft. The VH and VL sequences from the B4 mAb hybridoma were cloned, linked (VH-VL) and expressed as an scFv with an N-terminal His-tag. To confirm that B4scFv recognizes a post-ischemic graft, His-tagged B4scFv was administered after reperfusion, and confocal analysis of graft sections subsequently performed.
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Preparation and in vitro characterization of neoepitope-targeted complement inhibitor,
B4scFv-Crry
To prepare a targeted complement inhibitor, the extracellular region of Crry was linked to
B4scFv. The resulting B4scFv-Crry fusion protein had the expected MW by SDS-PAGE (64 kD, not shown), and the activity of the complement inhibitor was retained ( Figure 4 ). Note that this is an untargeted system since the B4 epitope is not expressed on zymosan particles, and that while B4scFv-Crry exhibits complement inhibitory activity, B4scFv does not.
Effect of B4 scFv and B4 scFv-Crry on graft IRI and inflammation
Allograft recipients were treated with B4 scFv, B4 scFv-Crry or PBS vehicle immediately posttransplantation, and serum levels of cardiac troponin I determined 48 hours post-transplant.
Compared to vehicle treated controls, recipients treated with either B4scFv or B4scFv-Crry had significantly and similarly reduced levels of serum cardiac troponin I ( Figure 5A ). Grafts were also assessed for histological evidence of injury and inflammatory cell infiltration 48 hours after transplantation. Consistent with cardiac troponin I levels, grafts from B4scFv-Crry and B4scFv treated recipients also had significantly lower injury/inflammation scores than grafts from vehicle treated recipients ( Figure 5B ). Natural antibody repertoires are likely to vary significantly in humans and therefore we sought to investigate whether B4scFv-Crry would be efficacious in the presence of high serum levels of an antibody that does not recognize the B4 not shown), and the activity of the complement inhibitor was retained (Figure 4 4 ). ). . N N Not ote e th th hat at at t t thi his s an untargeted system since the B4 epitope is not expressed on zymosan particles, and that wh whil il ile e B4 B4 B4sc sc scFv Fv Fv-C Crr rr rry y y exhibits complement inhibit tor or o y y activity, B4sc c cFv F F d doe oe oes s not.
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epitope. Therefore, using the same allograft model which has a full repertoire of natural antibodies, we supplemented the natural antibody response of the transplant recipient with 0.1 mg of C2 mAb prior to transplant, and then treated with B4scFv-Crry. We demonstrate that even in the presence of a high concentration of C2 mAb, B4scFv-Crry significantly reduced injury compared to controls ( Figure 5A and B), and the difference between the two B4scFv-Crry treated groups was not significantly different.
To further investigate how B4scFv and B4scFv-Crry modulate the inflammatory environment, we determined the effect of each molecule on graft levels of the cardiotoxic cytokine IL-6, and the macrophage and neutrophil chemokines MCP-1 and KC, all of which are associated reperfusion injury and the onset of rejection 10 . At 48 hours post-transplant, B4scFv-Crry treated recipients had significantly reduced graft levels of IL-6 and MCP-1 compared to PBS treated controls ( Figure 5C ). IL-6, but not MCP-1 levels were significantly lower in grafts from B4scFv treated recipients compared to untreated control recipients. Graft levels of KC at 48 hours post-transplant were not altered by treatment with either molecule, but it has been shown that KC levels peak within the first 24 hours after transplantation 10 .
IgM and complement deposition in grafts
The impact of B4scFv and B4scFv-Crry on IgM binding and C3d deposition in grafts was ho hour ur u s s s po po post st-t -t -tra r rans nsp p pla an ant t we we ere re n no ot o a a alt lt lter er ere ed ed b b by y y tr tr tre e eatm tm tmen en nt t wi wi ith th h e e eit it ithe he er r r m mo mole le lecu cu cul le, , bu bu ut t t it it it h ha as as b b bee e en sh sho ow own n n hat KC leve els ls s p p pea ea ak k k wi wi with th hin n n t t the he h fi fi firs rs rst t 24 2 2 h h hou ou ours rs rs a a aft ft fter er r t t tra ra ans nspl pl plan an anta ta tati ti tion on on 10 10 10 . . difference with PBS treated controls did not reach significance. At 48 hours post-transplantation, however, significant reductions in both IgM binding and C3d deposition was seen only in grafts from B4scFv-Crry treated recipients (Figure 6 ).
In vivo kinetics and biodistribution of B4scFv-Crry and B4scFv
To determine the circulatory half-life (t 1/2 ) of B4scFv-Crry and B4scFv, the proteins were injected i.v. into C57BL/6 (recipient) mice, and plasma levels of each protein determined at different times post-injection. There was a similar two-phase elimination profile for both proteins, with the bulk of injected protein eliminated in an initial rapid clearance phase. For B4scFv-Crry there was a fast phase t 1/2 of 9.7 mins and a slow phase t 1/2 of 5.5 hours, and for
B4scFv there was a fast phase t 1/2 of 6.9 mins and a slow phase t 1/2 of 7.0 hours ( Figure 7A) . A similar two-phase elimination profile has been shown for other biologics, including untargeted
Crry (Crry-Ig), although the second phase t 1/2 for Crry-Ig was considerably longer (40 hrs) 11 .
Previous studies have shown that for untargeted Crry, systemic complement inhibition and a high dose (up to 3 mg) is required for therapeutic benefit in various mouse models of disease 7, [11] [12] [13] [14] . In the current study, significant therapeutic efficacy is seen with a 0.2 mg dose of B4scFv-Crry and, at an early time point, with a molar equivalent dose of B4scFv (0.1 mg). Since preferential accumulation at the target site would be expected to translate to a lower dose requirement for therapeutic benefit, we performed a biodistribution study with the two proteins.
125 I-labeled B4scFv-Crry or B4scFv was injected into recipient mice immediately after heart transplantation, and tissue distribution of radiolabel determined 6 hours later. In addition to being present in the circulation, both 
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Data shown above in Figure 6 demonstrate that B4scFv-Crry and B4scFv similarly protect against graft IgM and C3d deposition at 6 hours post-transplantation, but that only grafts from B4scFv-Crry treated animals display reduced IgM and C3d deposition at 48 hours posttransplantation. These differences cannot be attributed to differences in circulatory half-life of the proteins (see above), so we performed an additional kinetic study to determine whether there are differences in the amount of each protein that localizes to the graft, or whether there are ransplantation. These differences cannot be attributed to differences in circulato ory r ry h h hal al lf-f-f-li li life fe fe o o of f he proteins (see above), so we performed an additional kinetic study to determine whether there ar re e di di diff ff ffer eren en ence ce es in in n t t th he amount of each protein that at at lo o ocalizes to the e gr g g af ft, t, t t o o or r whether there are d di diff f fer e ences in r ret et ten n nti i ion on t t tim im ime e of of of th the e e p pr pro o ote e eins in n n the e g graf f ft. Here, we demonstrate a key role for natural IgM in post-transplant cardiac IRI, and identify pathophysiologically important neoepitopes expressed in a transplanted heart. Although most natural IgM Abs that have been characterized are polyreactive, they nevertheless recognize a specific set of epitopes, and we demonstrate that two mAbs characterized here are specific for stressed or injured cells. The two mAbs, B4 and C2, were similar in terms of their cardiac graft binding characteristics and ability to restore cardiac graft IRI in Rag1-/-recipients. We subsequently focused on B4 mAb for therapeutic development since it is known that annexin IV is expressed on hypoxic human endothelial cells 4 , and IgM reactivity for annexin IV is present in human serum 5 .
It is nevertheless important to note that available evidence indicates that self-reactive Abs of multiple specificities exist, and while these Abs which are pathogenic when engaged are injury specific, it is less clear whether there are differences in tissue specificity. For example, B4
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an nd d d C2 C mAb n neo eo opi ito op p pes s s ar ar are e e al al also so e e exp xp xpre re ess sed i in n pos s st--i ische he hemi mi ic c mo mous use in int t tes st tin ine e e Although still systemic, anti-C5 mAb inhibits C5a and MAC generation without blocking the generation of C3 complement activation products that are important for host defense. However, in clinical trials, C5 blockade provided limited benefit for the treatment of ischemic heart disease 21 . Also, although anti-C5 mAb treatment can synergize with CTLA-4 to prolong graft survival 22 , C3 activation in the graft still occurs 23 , which may prime an alloimmune response. In this context, recent studies demonstrated an important role for graft endothelial C3a (and C5a) in priming allogeneic T cell responses 24, 25 . Two other strategies to overcome the problem of systemic inhibition have been investigated in the context of transplantation. One involved organ perfusion ex-vivo with a complement inhibitor linked to a membrane-inserting fatty acid component. Using this approach, a lipid-tagged fragment of CR1 localized within rat kidneys and provided protection from IRI 26 . The second approach specifically targeted complement inhibition to sites of C3 deposition 10, 27 . In this approach, complement receptor 2 (CR2) that additional immunosuppressive effect of systemic complement inhibition. One ap pp p proa o o ch ch ch t t to o o t alleviate such concerns is to target the terminal complement pathway with anti-C5 mAb therapy.
Al Alth th hou ou ugh gh gh s s sti ti till ll sys ys yste te temi m c, anti-C5 mAb inhibits C5 C5 5a a a and MAC gene ne erati ion on on w without blocking the g gen ne neration of C3 C3 C3 c com mpl plem em emen en ent t ac acti ti iva va vati tion on on pro o odu u ucts s th h hat a ar re re i imp mp m or orta tant nt f f fo o or h h hos os st t t d de defe fe ens ns n e. e. e Ho Ho owe we ev ve er, n n c c cli li ini ni nica cal l tr tr tria ia ials ls, , , C C5 5 b bl loc ck ckad ade e e pr pr rov ov ovid id ided ed d l lim im imit it ited d d b be e ene e efit t t fo fo for r r t th the e e tr tr t e ea eatm tm tmen en nt o of of i i isc sc s he he h m mi mic c c he e ear r rt t di di ise seas ase binds C3d was linked to a complement inhibitor, and such constructs protect against complement-dependent injury in various mouse models (reviewed in 28 ). One such construct, CR2-fH (TT30) is currently in clinical trials. While CR2-mediated targeting of complement inhibition is effective, there are a number of advantages with the targeting strategy described here for ameliorating post-ischemic injury. First, it will target the proximal event in complement activation. Second, the targeting vehicle itself contributes to therapeutic activity by blocking the binding of complement activating pathogenic IgM, which will in turn reduce the binding of C1q and MBL, which can impact inflammation, endothelial activation and cell trafficking 29 . Third, B4scFv-Crry has a considerably shorter circulatory half-life than CR2-Crry (at least in mice), which is a beneficial characteristic since it reduces systemic effects. Fourth, the current strategy may be more specific for sites of stress/injury since CR2 also binds other ligands, such as IFN 
Cell lines and antibodies
The B4 and C2 hybridoma cell lines expressing IgM mAbs were isolated following the fusion of spleen cells from unmanipulated wt C57BL/6 mice as described 1 . The specificities of these mAbs have been determined; B4 mAb recognizes annexin IV 1 and C2 mAb recognizes a subset of phospholipids 2 . As a control Ab, we used IgM mAb F632, expressed by a hybridoma isolated from mice immunized with 4-hydroxy-3-nitrophenylacetyl (NP)-KLH and screened against NP-BSA, as described 1 .
Transplantation Studies
Male C57BL/6, Rag1-/-on C57BL/6 background, and BALB/c mice were used in these studies. All mice were 8-10 weeks old and between 20-30 grams, and were purchased from the Jackson Laboratory. Heterotopic abdominal heart transplantation was performed as described 3 . Graft function was assessed by manual palpation and grafts were harvested at 6 or 48 hours post-transplantation. For isograft studies, we used the All antibody administrations and therapeutic treatments were administered i.v. in a volume of 100 µl, immediately post-transplantation. Dosing was based on previous studies using CR2-Crry in models of IRI 3, 4 . All animal procedures were performed according to approved experimental protocols, in accordance with institutional animal care guidelines of the Medical University of South Carolina.
Histology
For histological examination, tissue blocks were placed in 10% buffered formaldehyde solution for 48 hours before being embedded in paraffin. Four µm heart sections were stained with H&E stain, and sections scored by a pathologist (C.A./M.G.) who were blinded to the experimental group, using a semiquantitative histology scoring system.
Sections were scored 0-3 in 4 categories for evidence of epicardial, myocardial and endocardial damage, and inflammatory cell infiltrate, where 0 = no damage/infiltration, 1 = mild damage/infiltration, 2 = moderate damage/infiltration, and 3 = severe damage/infiltration, as previously described 3 . Results are expressed as cumulative scores from 0 to 12. Cardiac enzyme troponin I activity was measured as an index of cardiac damage using an ELISA kit (Life Diagnostics).
Immunohistochemistry and fluorescence microscopy
Paraffin-embedded heart sections (4 µm) were stained using antibodies directed against C3d (R&D Systems), IgM (Cappell), MBL-A and C (Hycult). For visualization, Vector
Laboratories ImmunoEdge detection kits with diaminobenzidine chromogen development was used (Vector Laboratories). Specificity of staining was assessed by omission of primary Ab and by use of an isotype control. Immunohistochemistry was scored semiquantitatively on scale of 0-3 as described previously 5 . For cellular localization of B4scFv binding, His-tagged B4scFv was injected immediately posttransplantation. Six hours post-transplantation, native and transplanted hearts were removed and embedded in OCT (Surgipath), and 5um sections cut for analysis by immunofluorescence microscopy as described 6 . scFv binding was assessed using an anti-His FITC antibody (ThermoScientific), and sections were subsequently counterstained with an anti-CD31-Alexa 555 antibody (Molecular Probes) to visualize endothelial cells.
Cytokine and Chemokine analysis
MCP-1, KC, and IL-6 were measured in heart allografts harvested at 48 hours posttransplantation. Hearts were homogenized, and protein extracted from homogenized tissue as described 3 . Chemokine/cytokine levels were measured using ELISA kits (R&D Systems), and levels normalized by total protein concentration calculated by BCA protein assay (ThermoScientific).
Plasmid construction
For construction of B4 and C2 ScFv expressing plasmids, mRNA was prepared from corresponding hybridomas using the Oligotex Direct mRNA Mini Kit from Qiagen. cDNA corresponding to mRNA was synthesized using the Qiagen OneStep RT-PCR Kit, with primers for variable heavy (VH) and variable light (VL) chain domains, designed based on the description of Amersdorfer et al. 7 . PCR products of correct size (approximately 350-400bp) were cloned into the PCR 2.1 cloning vector using the TOPO-TA cloning kit from Invitrogen. Positive colonies were sequenced and aligned using NCBI blast database. After identification of plasmids containing positive VH and VL chain cDNA sequence, a second round of PCR was conducted to amplify VH and VL chain cDNA. A restriction enzyme site (BamH1), a CD5 signal peptide sequence, and a His tag (6X) sequence was added to the 5' end of the VH chain. A linker sequence (G 4 S 2 ) 2 was added to 3' end of the VH chain and linked to the 5' end of the VL chain. Another restriction enzyme site (HindIII) was added to the 3' end of the VL chain for cloning. Gel purified VH and VL fragments were linked by overlapping PCR and purified products inserted into pcDNA3 expression plasmid (Invitrogen) as described 8 . For construction of the B scFv-Crry expression plasmid, the B4scFv sequence was linked to the extracellular region of mouse Crry (residues 1-319 of mature protein, GenBank accession number NM013499) by overlapping PCR with the linker (G 4 S 2 ) 2 , and OKT3
light chain signal peptide sequence added to the 5' end of the VH chain. The constructed plasmid was cloned into pcDNA3 plasmid for expression using described techniques 8 .
Protein expression and purification
Expression plasmids were transfected into CHO cells with FuGene HD transfection reagent (Roche Applied). Positive clones were selected by limiting dilution as described 8 and protein expression quantified by anti-His tag ELISA and dot blot. B4 and C2 scFv were purified from CHO cell culture supernatant by affinity chromatography using a metal chelating column from Qiagen. B4scFv-Crry was purified by anti-Crry mAb 5D5 affinity chromatography using previously described conditions 4 . Purity was >90% for all proteins as assessed by SDS-PAGE.
In vitro binding and complement inhibition assays
